Medivation Announces Treatment Of First Patient In Phase 2 Trial Of Dimebon(TM) In Huntington’s Disease
Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in its Phase 2 trial of Dimebon(TM) to treat Huntington’s disease. Medivation has expanded patient enrollment in the trial by 20 percent — to 90 patients — in order to enhance the ability to detect differences between Dimebon and placebo.
